C.R. Bard, Inc. (BCR) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts BCR Hot Sheet
Price: $331.24 --0%
Financial Fact:
Other (income) expense, net: 115.8M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Other (income) expense, net: 115.8M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
C.R. Bard, Inc. (NYSE: BCR) reported Q2 EPS of $1.42, $0.04 better than the analyst estimate of $1.38. Revenue for the quarter came in at $759.9 million versus the consensus estimate of $750.91 million.
Timothy M. Ring, chairman and chief executive officer, commented, "Our operating results this quarter exceeded our expectations. We continue to focus on the execution of our investment plan, which we believe will shift the mix of our portfolio to faster growing products and geographies and contribute to long-term sustainable leadership positions in our markets."
For earnings history and earnings-related data on C.R. Bard, Inc. (BCR) click here.
Timothy M. Ring, chairman and chief executive officer, commented, "Our operating results this quarter exceeded our expectations. We continue to focus on the execution of our investment plan, which we believe will shift the mix of our portfolio to faster growing products and geographies and contribute to long-term sustainable leadership positions in our markets."
For earnings history and earnings-related data on C.R. Bard, Inc. (BCR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
